The combination of flexible and robust immunoassay technology with the sensitivity of DNA as a signal amplification template is realized in Immuno-PCR ("IPCR"). Classical ELISA is converted to IPCR by exchange of antibodyenzyme detection conjugates with antibody-DNA conjugates. The value of ultra-sensitive analytics deriving from this for pharmaceutical R&D is threefold: (I) Deeper understanding of biomolecular interactions for the development of new compounds. (II) Monitoring of compounds at very low concentrations in toxicokinetic and pharmacokinetic clinical studies. (III.) Control of compound functionality and therapeutic effects by surveillance of characteristic biomarkers and/or immunogenicity reactions. This review summarizes background information about general selection of IPCR targets, actual standard assay procedures and work with biological matrices. Quantitative real-time detection as well as optimized reagents and protocols revealed a typically 100-10,000-fold increase in sensitivity and a broad dynamic range compared to ELISA. Case studies are discussed for (I) the analysis of biomolecular interaction with proximity ligation technologies and IPCR, (II) pharmacokinetic studies of novel drugs with validation data for assay precision and recovery and (III) biomarker profiling, including cytokine multiplex assays and polyplex trace analysis in extremely small sample volumes. In a survey of results from recent innovations, the potential of this emerging field of applications is evaluated for novel pathways in study design and analytics.
INTRODUCTION The Universal Tool for Highly Sensitive Biomolecular Detection
With the biotechnological evolution in rational design of active pharmaceutical ingredients, a twofold challenge arises:
(I) To achieve an increased understanding of functional compounds in the interacting network of life, the need for adequate analytical techniques is ever increasing.
(II) To trigger, control, and monitor a desired response by minute manipulation of carefully tailored, highly efficient compounds, a sensitive, robust, and flexible detection of biomolecules is required.
In case of nucleic acids, the polymerase chain reaction ("PCR") [1] with its cyclic repetition of exponential target amplification has become a prime tool for the analytical scientist. This key technology of modern bioanalytics unifies uttermost sensitivity down to a single-molecule-level with a nowadays well established robust and quantitative experimental protocol [2] [3] [4] [5] [6] . PCR has thereby dramatically changed the possibilities of analytical technologies, introducing innumerable novel applications in forensics, diagnostics and research.
*Address correspondence to this author at the Chimera Biotec GmbH, EmilFigge-Str. 76a, 44227 Dortmund, Germany; Tel: +49 231 9742 840; Fax: +49 231 9742 844; E-mail: info@chimera-biotec.com But nucleic acids are merely a subspecies of active biomolecules. Lacking a similar universal amplification technology for the broad variety of interesting biomolecular targets like antibodies, enzymes, transmitters, etc., unlocking the advantages of ultra-sensitive detection for these analytes requires an alternative strategy. The solution is an addition of DNA signal enhancement potential to conventional immunoassay formats: By taking a nucleic acid sequence as an amplification template and linking it with the target molecule of choice, the technologies developed for the detection of nucleic acids can also be applied to almost any analytic challenge.
A combination of specific antibodies for analyte recognition and a DNA marker for signal generation is therefore a versatile tool to improve assay sensitivity. This concept was introduced in 1992 as Immuno-PCR ("IPCR") by the workgroup of Cantor et al. in Boston, bringing together the world of protein-and DNA-analytics [7] [8] [9] [10] (Fig. 1) .
Right from the beginning, it was observed that the IPCR approach typically improves the sensitivity of conventional Enzyme Linked Immuno Sorbent Assays ("ELISA") by a factor of 100-10,000 (Fig. 2) , depending on quality of antibodyantigen interaction, antibody-DNA linking technology and general set-up of the assay [11] . As these parameters are indeed the central points for good assay performance, they will be discussed in more detail below.
The robustness of immunoassay target detection and the stability of DNA molecules as a marker molecule compared to e.g. photo-bleaching in fluorescence or degradation and safety hazards in radioimmunassays make IPCR technology well suited for ultra-sensitive routine applications. Additionally, information encoded in the DNA allowed for other benefits such as self-organization of reagents [12] [13] [14] , simultaneous detection of multiple detection conjugates labelled with different DNA markers in multiplex assay formats [15, 16] or the translation of DNA markers to functional compounds in target detection [17] [18] [19] [20] [21] .
Joining the well-established ELISA-technology with the sensitivity enhancement accessible by DNA-markers paves the way to new analytic approaches in various application fields. The following paragraphs will focus on practical considerations for assay set-up (1) and typical applications in the field of pharmaceutical development and related topics (2) ; thereby evaluating how the possibilities of ultra-sensitive IPCR assays interlink with the requirements of practical use.
PRINCIPLES OF IMMUNOASSAY DESIGN RE-VISED
While the general design of immunoassays is nowadays a routine procedure documented and discussed in numerous comprehensive manuals and textbooks (e.g. [22] [23] [24] ), the addition of DNA as a label molecule modifies some typical ELISA parameters in a distinctive way. Thus, special considerations of potential trouble sources as well as benefits for this field of work are essential. As summarized in Fig. (3) , there are mainly three characteristic questions which demand attention in the development of ultra-sensitive assays by use of protein-DNA reagents:
What to Detect?
The most basic question is of course the compatibility of analytical target and detection technology. An obvious choice for ultra-sensitive analytics is the detection of extremely low levels of biomolecules which are inaccessible by conventional analytics. Due to the high similarity of Fig. (1) . Schematically representation of ELISA and Immuno-PCR (IPCR). Antigens (red) were detected by specific binding against capture-and detection-antibodies (blue), following the general principle of immunoassay target recognition. Antibody-enzyme conjugates as used in ELISA transform one molecule of substrate into one molecule of product. By exchange of antibody-enzyme conjugates with antibody-DNA conjugates, a more efficient cyclic signal amplification is accessible as the amount of DNA is effectively doubled in each step of a polymerase chain reaction (PCR) and products of one amplification round are substrates for the next. Thus, the polymerase enzyme allows for an exponential signal amplification compared to the linear relation between substrate and product in conventional ELISA.
Fig. (2).
Typical results of IPCR sensitivity enhancement: (A) In combination of tailored antibody-DNA conjugates and real-time detection (see below), a customized Imperacer ® assay [82] was developed for detection of the drug mistletoe-lectin (abnoba VISCUM Fraxini 20 mg) in pharmacokinetic studies of human serum. 10 l of human serum sample material were diluted 1:3 in sample dilution buffer for a total assay volume of 30 l/well. Incomparison with a control ELISA carried out under identical conditions, an approx. 100-fold increase in sensitivity was observed [74, 76] . (B) In another application, an existing rotavirus ELISA kit was adapted to the IPCR / Imperacer ® protocol. Here, ELISA sensitivity in buffer and stool samples was enhanced 1000-fold, demonstrating robustness of the assay approach for both, drug detection as well as monitoring of diseases [30] . Remarkably, exponential signal amplification in IPCR is also responsible for an increased linear dynamic range of the correlation between log concentration and measured signal, revealing a quantification window of several orders of magnitude antigen concentration. Fig. (3) . The three prime questions for IPCR assay design.
ELISA and IPCR, all targets qualified for conventional immunoanalytics by size, stability and the availability of antibodies are also prime targets for sensitivity enhancement with an marker-DNA label. Indeed, there is a broad range of IPCR and related assays including almost all sources and types of biomolecules in concentrations down to a few 1000 molecules and below [9, 11, [25] [26] [27] . However, it should be noted that kinetical considerations of antibody-antigen binding and the parameters of analyte diffusion to the binding molecule strongly suggest a level of approx. 1000 target biomolecules in a typical assay volume as a theoretical lowest detection limit for standard immunoassay set-up [23, 28, 29] . A survey of IPCR detection limits confirms this anticipated effect of binding dynamics for the majority of reported results so far [9] . While DNA amplification allows for the detection of even single target molecules, the required coupling steps between DNA-labelled detection molecule and target increases the amount of molecules necessary for signal generation. Furthermore, due to reagent incubation steps in the immunological detection part, marker DNA is present in all test points of a single assay, including negative controls without antigen. For exceeding the therefore unavoidable background caused by unspecific bound marker DNA, a minimum amount of target molecules is required to induce significant signals.
Nevertheless, even a theoretical IPCR detection limit of 1000 non-DNA biomolecules lead to an increase of sensitivity in the range of several orders of magnitude compared to classical immunoanalytics. Typically, IPCR is reported to reveal an approx 1000-fold improvement in detection limit compared to ELISA [9] . For an exemplary biomolecular protein target of approx. 50-100 kD size, this equals an detection limit in the sub-picogramm range which is especially interesting for lower physiological levels of many biomarkers like e.g. the cytokine panel. Additionally, in case of virus surface proteins, a single virus contains a large number of target proteins: Therefore, even if no single protein-molecule detection is accessible with IPCR, single virus particles and also fractions thereof are detectable with IPCR of surface proteins (Fig. 2B) [25, 30, 31] . The same is true for the detection of cells presenting a surface antigen and was demonstrated with pre-implantation diagnostics of a histocompatibility complex on blastocysts [32, 33] Thus, ultra-sensitive protein assays are complementing DNA/RNA analytics for virus infections or cell expression studies by confirming the actual presence of expressed proteins and also provide a tool for characterization of virosome / surface protein vaccines without the actual presence of viral nucleic acids.
But besides the evident field of absolute sensitivity enhancement, the combination of target recognition and DNA amplification opens up additional pathways in assay design.
First of all, sensitivity gain in ELISA by e.g the choice of different substrates or improved assay conditions is mainly a shift in a narrow detection window [34] . For alternative ultra-sensitive signal amplification technologies such as ElectroChemiLuminescence (ECL) or IPCR, the additional sensitivity is added to the conventional detection window, thus broadening the linear detection range to 4-6 logs of concentration. By the enhanced linearity of these assays, data analysis and validation of results is also facilitated as a simple linear regression became sufficient for calculation of concentrations in a much broader range (Fig. 2) .
These applications are therefore well suited for quantitative detection of targets. As it is possible to detect high-and low-level samples with the same assay format, kinetic series with high starting concentrations and low endpoints [35] as well as comparisons between samples of naturally low and induced high levels of targets (and vice versa) are especially benefiting from this broadening of detection range.
Additional sensitivity also surpasses a simple improvement in detection limit in other fields: For a number of analytic challenges, such as small animal model systems, miniaturized cell culture preparations, or hart-to-obtain body fluids, sample size is significantly limited. The added sensitivity of novel assay formats increases the number of different tests which can be performed with small sample volumes down to single microliters [36] or limited amounts of cell culture [37] , thus adding valuable layers of information by statistically significant multiple determinations and/or additional parameters for testing [9, 25] .
With IPCR and related technologies, it is therefore possible to detect and quantify a complete panel of targets from a single source with extreme sensitivity and specificity, either in simultaneous multiplex or separate polyplex assays (see also 2.3, below) [9] . This approach also proposes a change in animal study design as it became possible not to rely on different small animals for different sample drawing times in toxico-and pharmacokinetic experimental series but to use individual animals for all required samples over the course of the experiment. The small amount of sample material needed for each drafting leads to the possibility not to dispatch or exceedingly stress small animals. Therefore, e.g. five rats would allow to measure five complete kinetic series instead of only five samples and inter-individual variations are circumvented by consistent sets of data for each individual. Smaller sample sizes also improve the process of sample drawing. As an example, standard blood sample collection for quantitative analytics typically requires the expertise and effort of medically trained and qualified personal to draw millilitre amounts of blood with a syringe. With improved sensitivity, sample collection could be simplified to the use of easier accessible drops of capillary blood as microlitre amounts are already sufficient [38] .
Ultra-sensitive analytics is thus well qualified for various sample sources and sample formats. Regarding detection targets, the flexibility of IPCR assays is similar to all conventional immunoassays: As long as specific and stable primary antibodies are available against a given antigen, an appropriate IPCR assay is also accessible.
One major strategy in assay set-up utilizes indirect assay formats, targeting either the species or the label of a given primary antibody [39] . Label-specific detection conjugates such as e.g. anti-biotin reagents allow for adaptation of IPCR to ELISA assays which already utilize biotinylated primary antibodies by exchange of detection reagents. With general antibody-specific detection reagents, it is additionally possible to detect immune-response curves, e.g. in immunogenicity studies [40] .
For direct target detection (see 1.2, below), a number of different assay formats are available. Regardless of indirect or direct detection, all IPCR assays share the common truth of immunoassay design that each assay is only as good as the antibodies involved. Therefore, high specificity and binding strength of the utilized antibodies is an important prerequisite for assay design [23] . But in contrast to conventional ELISA, IPCR allows for the compensation of certain antibody weaknesses by the benefit of high sensitivity: Low binding strength of otherwise high specific antibodies such as single chain fragments was successfully circumvented by improved assay sensitivity in IPCR [41] . Also, unwanted cross-reactivity of antibody pairs and/or DNA in simultaneous multiplex assays is avoided by separating multiplex analysis in several small polyplex assays [9] .
If, in contrast, more than one excellent antibody is available against a given target with epitopes located near to each other, a liquid phase assay format using proximity ligation becomes feasible [42] [43] [44] [45] (see also Fig. (6) and 2.1, below) . This assay set-up is especially interesting for measurement of sterical changes in the target as the position of the bound antibodies in relation to each other determine if a signal is generated [46, 47] .
Finally, for small molecular targets with only one immunogenic recognition site, different formats for competitive IPCR assays were reported [48] [49] [50] , thus completing the full range of immunoassay formats for ultra-sensitive analytics.
The properties of IPCR and related technologies were explored in a broad range of application fields summarized in Fig. (4) , including tumor markers [19, 36, 45, [51] [52] [53] [54] , virus antigens [30, 31, 37, [55] [56] [57] [58] [59] [60] [61] , pathogens & toxins [59, [62] [63] [64] [65] [66] [67] , hormones & neurotransmitters [15, 16, 49, 50] , cytokines [44, [68] [69] [70] [71] [72] [73] , drug monitoring [74] [75] [76] [77] [78] [79] , antibody detection [39, 61, 80] and various other biomarkers such as surface antigens in preimplantation diagnostics [32, 33] or targets in the field of neurodegenerative diseases [41, 81] . IPCR was thereby found to expand the properties of conventional immunoanalytics for all kinds of targets.
How to Detect?
The introduction of nucleic acids as a label in immunoassays provides a dual need for efficient technologies to a) link the marker with the target of choice and b) detect nucleic acid material after amplification. These two challenges were resolved by taking experience from different fields of bioanalytics and combining them in an optimized and standardized quantitative IPCR protocol [9, 82] .
Regarding the coupling of marker and target, a number of different strategies were described [9, 10, 25] (Fig. 5) : Initial protocols of IPCR made heavy use of different binding protein systems such as (Strept)Avidin/biotin [10, 14, 28, 83] or protein A / antibodies [7, 84] to label antibodies with DNA in a modular multi-step approach (Fig. 5 A&B) . These protocols are highly flexible in adaptation to different research projects due to simple exchange of e.g. biotinylated detection antibodies. The method of "universal IPCR", introduced by Zhou et al. in 1992 [28] applies a sequential incubation of target specific primary antibody, primary-antibody specific biotinylated secondary antibody, coupling protein streptavidin and biotinylated DNA. This strategy was successfully applied in the majority of IPCR analytics so far and revealed excellent performance [9, 25] . Nevertheless, the amount of parameters involved in this assay set-up is far too complex for routine applications as the different reagent coupling steps require an extremely careful optimization process for each new analytical target [85] [86] [87] . The experimental expertise required to master a robust application of this challenging protocol certainly explains why only a handful of workgroups have implemented IPCR so far as an analytical tool instead of a field of experimentation for method development.
As an alternative, direct conjugates of antibodies and DNA were synthesized either by chemical crosslinking [15, 16] (Fig. 5C ) or indirect pathways utilizing natural and nature-analogous technologies of native chemical ligation [88, 89] (Fig. 5D ) or phage display [41] (Fig. 5E) . In comparison, performance of direct conjugates was found superior to stepwise coupling in terms of sensitivity, handling, robustness, and assay duration, making IPCR finally suitable for routine applications [54, 82] .
In a number of applications, assays including antibody-DNA reagents were found similar to conventional ELISA protocols, making the practical performance of these kind of assays accessible for anyone with experience in standard immunoassays. IPCR is typically carried out in the familiar 96 well microplate format and is thereby compatible with the appropriate standard ELISA equipment like multichannel pipettes, incubators and automated plate washers. Multi-well microplate formats also facilitate the application of multiple determinations for analysis of statistical significance of results. While the use of at least double determinations should be a standard approach to reliable quantitative analysis espe- Since its first introduction in 1992 at the model protein BSA [7] , IPCR assays were applied to a broad range of analytical targets. IPCR was found compatible with all major immunoassay formats, including (A) direct assays [82] , (B) indirect assays for detection of non-labelled target-specific primary antibodies [39] , (C) sandwich assays for detection in biological matrices [57] , (D) indirect sandwich assays in universal IPCR [28] , (E) bridging assays for immunogenicity detection [40, 136] and (F) competitive assays for small molecule detection [49, 50] .
cially in ultra-sensitive analytics, it is sometimes discarded due to assay format and/or intended minimization of work. Single measurements, however, are only suitable for basic qualitative research and clearly not recommended for valid quantitative applications [90] [91] [92] . Here, the microplate format and the small amount of required sample material in IPCR analysis conveniently supports the use of significant multiple determinations [78] .
One major alteration compared to classical ELISA is however the actual choice of the microplate material. Best results were found when immunoassay and PCR signal amplification were carried out in the same modules without the need for additional transfer steps. To avoid the risk of crosscontamination and the additional handling in transfer steps [61, 68, 93] , a plate material and format is required which is compatible with protein immobilization in immunoassays as well as with the requirements of PCR thermocyclers [94] . Appropriate plates and modules are available from different sources, thus ensuring assay compatibility with well-spread 96well plate PCR instruments. Furthermore, plateindependent approaches such as functionalized glass [95] and bead-based assays [10, 31, 56, 96] were developed to address different handling and automatization challenges (Fig. 6 ).
For the actual amplification and detection of the DNA marker, the great advances in quantitative PCR [6] also proved to be extremely beneficial for IPCR. While first IPCR protocols described combinations of PCR and gelelectrophoresis or subsequent PCR-ELISA for DNA quantification [57, 58] , these approaches required additional work and materials. While end-point detection of amplified DNA is a methodically familiar approach to anyone quantifying DNA, it requires the handling of amplified DNA product, a major source for cross contamination. Furthermore, the post-PCR processing of DNA is time-consuming compared to conventional ELISA which effectively ends by adding substrate and placing the plate into the reading device. Especially gel-electrophoresis was found massively incompatible with the demands of routine quantitative analytics, revealing a decrease in sensitivity and a low overall precision [58] . In contrast, the application of real-time PCR probes and instruments [3, 5] proved itself to be highly advantageous for IPCR and can nowadays be considered as the method of choice for routine quantitative DNA amplification in PCR and IPCR [9, 39, 59, [97] [98] [99] [100] . A number of different realtime detection technologies are available and can be tailored to the DNA-marker of choice in IPCR [59] (Fig. 7) .
Optimized instruments allow for convenient assays performance and signal read-out [6] . The high assay precision which is typically associated with real-time PCR was also maintained for IPCR and related techniques [25, 30, 39, 53, 76, 79] .
In summary, the requirements of both, coupling targets and nucleic acid marker as well as subsequent detection of In the initial IPCR protocol [7] , an aggregate consisting of biotinylated DNA and a protein A / streptavidin (STV) chimera was coupled to an unlabeled antibody in a single step. The major drawback of this elegant approach is unspecific binding of protein A chimeras against all antibodies, thereby making the use of capture antibodies impossible. B: In the universal IPCR protocol, a detection antibody (1) was biotinylated previous to the assay. The biotinylated antibody (2) was coupled either with the target antigen or a primary detection antibody and stepwise incubated in situ with biotin-binding STV (3) and finally biotinylated DNA. While this modular approach allows for great flexibility and easy access to the reagents, it also requires multiple incubation and washing procedures and an extremely careful optimization of reagent concentrations. C: With direct covalent conjugation [15, 16] , convenient antibody-DNA conjugates are accessible which allow for a simplified assay protocol and high coupling efficiency. The downside of this approach is the necessary equipment and expert knowledge crucial for successful inter-bimolecular crosslinking. D: If a recombinant antibody fragment is used, the DNA of the binding molecule (1) can be fused with a short DNA fragment encoding intein (2) . The expressed protein thus includes an intein part (3) which directly binds to thiolated DNA. With this approach of native chemical ligation [88, 89] for conjugate synthesis, the actual coupling of DNA and protein is facilitated and occurs directed to a specific side of the protein. The price for this is of course the additional requirement of DNA/protein engineering and expression technology. E: A complete biomimetic way of linking antibodies and DNA is the use of phage-display technology [41] . Here complete phages expressing target-specific antibodies on the surface and containing antibody-encoding DNA as a marker are replacing artificial conjugates with all the advantages and drawbacks of working with complex biological systems. For all coupling technologies, protocols and nowadays in several cases also suppliers of biotinylated reagents, intein sequences or complete conjugation services are available. Fig. (6) . Independent from solid supports like microplate surfaces, IPCR was carried out in several semi-homogenous formats: In magneto-IPCR, capture antibodies were immobilized on magnetic beads or magnetosomes [31, 56] . The Bio-Barcode approach additionally utilized detection-antibody coated gold particles which were linked with the DNA marker to increase the amount of DNA coupled to the target antigen [131, [137] [138] [139] . Detection antibody reagents with multiple DNA markers generally increase the signal for specific antibody-antigen bindings and thereby improve signal-to-background ratios and sensitivity [25] . If the target protein offers two different epitopes in close proximity, two different short DNA fragments coupled with specific antibodies can be combined to a single amplification template: a.) The proximity ligation technology hybridizes a short connector ("splint", blue) against the two DNA labels and fixates the bridged DNA by addition of ligase. Afterwards, the long combined DNA template molecule was amplified by PCR [43] [44] [45] 71] or RCA [47] . b.) In NADIA (homologous "Nucleic Acid Detection Immunoassay") technology [104] , the two short DNA fragments are hybridizing partially with each other and the short double strand overlap is elongated by Taq enzyme for the formation of two long DNA templates. marker are nowadays fulfilled by a number of different highly efficient approaches, making the technology well suited for routine application.
Wherein to Detect?
For practical analysis of biological/medical sample material, the presence of a background matrix influencing assay performance is an undeniable fact.
Sample treatment always includes the deliberate choice of purification steps vs. the use of non purified material. While purification is essential for target isolation in several analytic technologies to achieve meaningful data, each purification step influences general sample stability and implies some kind of loss in analytic material. Additional work, reagents and time are required for each sample treatment step, interfering with the challenges of efficient routine analysis. For optimum analytical performance, the rule of thumb is thereby to use as much purification as necessary -but not more.
Here the ability of highly specific immunoanalytic technologies to identify targets even in the presence of other compounds in combination with the major enhancement in assay sensitivity by novel IPCR detection technologies became especially valuable as it allows to substitute sample purification by simple and fast sample dilution.
As shown in Fig. (8) , the concept of sample dilution improves assay performance by reducing the amount of potentially interfering compounds in a given sample (proteins, detergents), in combination with neutralization of detrimental assay conditions (e.g. pH value, digestion enzymes) and addition of sample stabilizers [24] . Typically, matrix proteins are offering a high potential for unspecific weak interactions of reagents so that undiluted biological samples are revealing high background signals which can be minimized by appropriate sample dilution [101, 102] . A reduced background signal is typically equivalent to a gain in sensitivity as the signals for low concentrations are better separated from negative controls. In standard analytic applications, however, sample dilution is always linked with a loss of the actual amount of analyte present in a given sample volume. The detection method for the reduced amount of target compounds has to compensate this effect. Therefore, novel highly sensitive detection technologies like IPCR are wellsuited for making use of the sample-dilution approach to improve detection limit and assay stability [34, 40, 78] .
Taking a step beyond treatment of sample material for robust and sensitive detection, the composition of the calibration curve is of prime importance for quantitative applications as required e.g. in dose-response or kinetic studies. Only a good similarity of quantification curve and sample material ensures correct data for calculated concentrations. In contrast, the required homogenous negative matrix material required for spiking of calibration curves absolutely similar to the intended samples is often hard to obtain. In the ideal case, monitoring of drugs allows the researcher to draw an individual negative control previous to application of the drug. The small sample size required for ultra-sensitive assays enables the preparation of complete spiked concentration series from a single negative control of approx 500 l, thereby ensuring maximum similarity between calibration curve and individual samples [78] . A similar approach is available for the detection of immune response / immunogenicity by utilizing sample material collected previous to immunization. But for typical intrinsic biomarkers, negative sample materials are not directly available. Furthermore, if pharmacological studies are performed in small animals, sample sizes of negative controls may be not sufficient for individual calibration curves. Pooling of negative matrices requires careful testing to avoid contaminations of the final pool and the use of standardized or artificial materials is not competently comparable to individual matrix variations. Here, the application of ultra-sensitive assays in combination with sample dilution offers an alternative strategy. If an individual sample is highly diluted, matrix properties become more and more similar to the properties of the dilution buffer, thus enabling the use of a concentration series in buffer as reference for quantification (Fig. 8) . Thus, the design of quantitative assay protocols is simplified and the significance of results is increased.
A final consideration regarding detection matrix is the ability of ultra-sensitive assays to allow for a shift in source material. A number of antigens such as marker proteins for neurodegenerative diseases have comparable high levels in cerebrospinal fluid which is, however, only available by stressful sample drawing. Typically, these markers are also Fig. (7) . For convenient detection of DNA-marker in IPCR, different real-time technologies were applied [4] . Different probes enabled the amplified DNA to trigger an increase in fluorescence which was measured directly during amplification. A.) Detection reagents like Ethidiumbromide, Pico-Green or SYBR-Green emit specific fluorescence after intercalation in double-strand DNA and are typically used for gel-electrophoresis in end-point determinations of PCR-products. They were also applied in real-time IPCR quantification [61] . As intercalation reagents have no sequence specify and will also detect erroneous side-products like primer dimers, the application potential in quantitative IPCR is limited. B.) In TaqMan ® technology [140] , an oligonucleotide probe (blue) containing a fluorescence reporter dye ("F", red) and a quencher ("Q") is added to the PCR reaction containing template (dark grey) and amplification primer (light grey). The probe hybridizes next to the primer on the target sequence and is destroyed by exonuclease activity of the Taq enzyme as the primer is elongated. Thus, fluorescence dye and quencher became separated which induces the signal. C.) The use of Scorpion ® reagents [141] which combine amplification primer and fluorescence detection element in a single sequence eliminates the need for additional probes. Here, a DNA hairpin loop containing fluorescent dye and quencher is linked to the primer sequence. After elongation of the primer during PCR, the hairpin loop unfolds and binds against the elongated primer, thus interrupting FRET between dye and quencher and generating the signal. While design of Scorpion sequences including the appropriate structural-supporting complementary sequences is quite challenging [142] , the final signal-inducing hybridization step is transformed to an intramolecular event which ensures maximum efficiency compared to reaction kinetics involving interactions between different molecules [143] . . The high precision of real-time PCR in double determinations is maintained in real-time IPCR and the curves are well separated from each other. Thus, the dynamic range for target antigen quantification covers several orders of magnitude as seen here at the example of IgG detection [97] . present in the blood, although at a much lower level. Here, ultra-sensitive analytics supplement and/or circumvent analysis of CSF as they enable the detection of neuromarkers in more easily accessible serum or plasma samples [103] . Taking this approach one step further, protein markers for monitoring of body functions such as muscle grow typically found in blood were also detected in saliva by IPCR, thus replacing blood collection by non-invasive sample drawing [9] .
IPCR APPLICATIONS IN DESIGN AND MONITORING FUNCTIONAL COMPOUNDS
With general IPCR functionality and potential as discussed in the previous paragraphs, a number of novel tools became available for the analytical scientist. The following application examples will focus on the use of selected methods for developing and testing new pharmaceuticals. The special challenges of this field of work are mirrored by the properties of ultra-sensitive analytics, thus offering new strategies for streamlining analysis of functional concepts and monitoring of drug application.
Biomolecular Interactions
Recognition of target compounds is the central key for biomolecular functionality. Enzymes and substrates, transmitter and receptor molecules or antibodies and antigens are optimized binding partners in the intricate metabolic network. Specificity and intensity of interaction are thereby deciding the degree of functionality, be it for substrateanalogous blocking unwanted bioactivity, artificial transmitter substances triggering specific response or antibodies intended for immunization or therapeutic use.
DNA-protein constructs allow for the sensitive detection of this kind of pharmaceutically important parameters in a variety of different ways (Fig. 9) . Spatial closeness of interacting compounds is addressed by proximity ligation and related technologies. Thus, a small distance of epiotopes in different biomolecules following a binding event is translatable into the generation of a DNA-marker as an amplification target [42, 43, 104] . [40, 89, 144, 145] ; C: Structural dynamics in the closeness of two epitopes either on the same or two different linking proteins are a prime target for proximity ligation reagents [42] ; and D: The interaction of DNA and proteins is utilized either for detection of DNA-binding/modifying proteins [100, 105] , or, by use of tailored aptamer sequences [106] , specific antigen detection [27] . In all applications, the use of DNA as a template for signal amplification enhances assay sensitivity compared to conventional labelling dyes.
The analysis of enzyme activity was enhanced by coupling DNA with an enzyme substrate. Banin et al. demonstrated this alternative approach to IPCR at the example of alkaline phoshatase detection with phosphorylated DNA. Following a digestion step which removed the nonenzymatically modified DNA, the presence of the enzyme was indirectly detected by PCR-amplification of the remaining de-phosphorylated DNA [105] .
In case of DNA-binding proteins, highly sensitive detection of protein-DNA interaction requires no modifications of the DNA but is directly accessible by real-time PCR amplification of coupled DNA. Following this approach, Hou et al. reported a technology for highly specific detection of DNAbound transcription factors by combination of single-strand oligonucleotide-protein interaction and subsequent digestion of non-coupled marker with ExoIII nuclease [100] . A re- Fig. (8) . For the detection of antibodies at physiological levels (typically >1ng) and comparison of different individuals, not absolute sensitivity but robustness against external influences defines assay functionality. While different undiluted antibody-containing matrices reveal massively different signals (left), an increase in dilution factor removes background effect and induces similarity in the relation of concentrations and signal. With the addition of stabilizing compounds to the sample dilution buffer, a high robustness against matrix effects is accessible even at lower dilution rates [25, 39, 40, 78, 79] .
versed application of DNA-protein binding in IPCR is the use of specifically designed aptamer DNA sequences [106] for identification of target proteins. Here, it is not the specificity of a given protein for DNA but the specificity of a tailored DNA which is utilized for assay design. The group of Landegren et al. applied the specificity of two tailored aptamers in an ultra-sensitive proximity ligation assay for cytokine platelet-derived growth factor (PDGF) without washes or separations [44] . This is only one example for the potential of aptamer technology in ultra-sensitive detection, recently reviewed in detail by Zhang et al. [27] . The use of aptamers generally combines the advantages of highly specific tailored binding molecules with the drawback of required complexitiy and expertise in generation of these biomolecular tools -a balance between functionality and effort also well known in the production of monoclonal antibodies for "classical" immunoassays.
For characterization of antibody-antigen interaction, the ELISA related immuno-PCR approach which utilizes antibody-DNA conjugates and also the linkage of antigens with DNA enables the researcher to increase assay performance in the whole bandwidth of immunoanalytic applications, including robust sandwich assays, direct assays and also competitive assay formats [9, 25] (Fig. 4) . Especially bridging and neutralization antibody assays in immunogenicity studies benefit from IPCR sensitivity, robustness and high drug tolerance [40] .
Monitoring of Pharmaceutical Compounds
In almost all steps in pharmacological development process, the enhanced sensitivity of IPCR and related technologies can be utilized advantageously (Fig. 10) . Especially the determination of toxicokinetic and pharmacokinetic properties of a given compound are essential for evaluation of drug metabolism. There are basically three challenges in this application where the benefits of ultra-sensitive detection became evident: a.) detection of low levels of target antigen, e.g. with low starting concentrations and/or in the later phases of drug metabolism b.) high robustness against biological matrices and individual variations c.) good quantitative data readout in a broad dynamic range.
At the example of an IPCR assay for the detection of recombinant [79] and native [76] mistletoe lectine, a cytostatic drug used in cancer therapy [35, [74] [75] [76] [77] [107] [108] [109] , the development and use of a tailored ultra-sensitive assay can be summarized:
As mistletoe lectines were reported for induction of strong metabolic reaction [108, 109] , emphasized by stimulation of immune response, application doses were expected to be very low. Furthermore, a decrease of free drug levels accessible for analysis in blood samples is typically observed for subcutaneous injection as the residual active compound has first to cross over from tissue to the blood circuit. Coupled with known lipophile properties of the lectine proteine familiy which induces functionality by cell-binding but also decreases solubility in aqueous solution / body fluids by aggregation, all these factors made kinetic studies of mistletoe lectin a very hard target for conventional ELISA. Key factors for an enhanced ELISA performance were increase of sensitivity by introduction of a target-specific antibody-DNA conjugate and sample dilution for minimization of matrix effects. The dilution buffer system contained detergent and additional stabilizers for increased target solubility and enhanced robust handling of sometimes inhomogeneous body fluids. Thus, IPCR detection enabled quantification of lectine below the detection limit of conventional ELISA with an approx. 100-fold gain in sensitivity and good compatibility with target levels observed in proband and patient samples [78, 79] . Fig. (10) . Development of new pharmacologically active components is a complex multi-step process. The enhanced properties of IPCR assays, including high sensitivity and robustness, small sample sizes, broad dynamic range and adaptability to multiplex / polyplex applications enable an increased performance for all steps of development.
Following initial experiments with spiked standardized and individual serum and plasma samples which also included evaluation of different antibodies for selection of the best antibody pair [79] , the assay was successfully used for quantification of kinetic studies.
In a clinical study of recombinant mistletoe lectin, over 40 individual patients were monitored in the course of 3 years (Fig. 11A) , demonstrating long-term stability of the assay. IPCR validation revealed parameters of 95 ± 19% target recovery in human serum, and 9 ± 5% average intraassay precision [78] . As the initial IPCR of mistletoe lectin was developed previous to standardized real-time IPCR protocols, it is interesting to compare IPCR / PCR-ELOSA combination with the nowadays used real-time IPCR format: Remarkably, the quantitative endpoint detection of amplified DNA marker required the inclusion of an additional internal competitor DNA to achieve the high resolution necessary for target antigen detection in the window of physiological concentrations [79] . In contrast, real-time qIPCR signal generation allowed for a more convenient assay set-up due to the high precision of improved marker detection. Here, validation revealed 95 ± 8% recovery and 1.7 ± 0.7% intra assay precision [74, 76] , respectively. In terms of antibody selection, the initial IPCR for mistletoe lectin utilized a polyclonal IgG as both, capture and detection antibody [79] . While this approach ensures minimized antibody cross-reactivity, the use of polyclonal antibodies is always limited by the amount of antibody available from a given source. The new IPCR was therefore adapted to the use of monoclonal antibodies for the target antigen, assuring a continuous supply of identical antibodies for different studies. This improved lectin assay ( Fig. 2A) was subsequently utilized for the detection of subcutaneously applied drug (Fig. 11B) [74] [75] [76] . The lectin initially present in the tissue after injection migrates to the serum and is analyzed there by IPCR. Low-level analysis was thereby required to made pharmacokinetic analysis of subcutaneous application of this drug accessible. Fig. (11) . Applications of IPCR in pharmacokinetic studies of mistletoe lectin. A: Recombinant lectin ("Aviscumin") was intravenously applied to a series of patients (P#1 -P#41) in the dose range of 10 ng/kg -2400 ng/kg. Shown is the maximum detected concentration in serum (Cmax) taken 1h after treatment. A linear relationship was observed between given dose and measured concentration [35, [77] [78] [79] . B: Native lectin ("abnobaVISCUM ® Fraxini 20 mg") was subcutaneously applied and subsequently detected by Imperacer ® . The assay allowed for recording of serum level profiles of the drug several hours after sc application. Note that the ELISA detection limit for mistletoe lectin detection is above 1 ng/ml in biological matrices (see e.g. above, Fig. 2A) . Therefore, IPCR was required to made the physiologically observed sub-ng/ml concentrations of target compound accessible for pharmacokinetic analysis.
The examples discussed above demonstrated the potential of IPCR to provide robust solutions for challenging kinetic studies. In addition, the use of antibody-specific IPCR detection conjugates allows for monitoring immune response and immunogenicity [40] or therapeutic antibodies [110] . Finally, every application of a drug is intrinsically linked to the keen observation of variations basal biomarker levels and the response of the treated illness. In the following case studies, it is therefore discussed how ultra-sensitive analytics supports monitoring the reaction of the organism to internal and external stimulations.
Surveillance of Characteristic Biomarkers
The complexity of living organisms is typically above single yes/no-answers. Similarly the detection of single compound as in monitoring the presence or absence of a given drug is not always sufficient for evaluation of the biological response. In contrast, a set of different biomarkers enables the recording of profile data and variations in this profile allow for a more in-depth analysis.
While DNA/RNA-profiles are nowadays accessible in miniaturized biochip formats up to the routine analysis of complete genome expression in a single experiment [111, 112] , the correlation of this nucleic-acid based information with the actual presence of the encoded proteins is much more challenging. The different properties of proteins compared to the robust nucleic acid molecule require much greater care in assay adaptation. For protein-profiling, a number of microarray based solutions were reported which always maintain a balance between versatility in the number of different analytes and sensitivity in the amount of antigen detectable in a given assay [113] [114] [115] . In most diagnostic and monitoring applications, a specific population of biomarkers adapted to the question of interest is sufficient, liberating the assay design from a compromising format which includes all kinds of proteins in favour of a significant selection and optimized assay conditions.
A prime example for a connected population of biomarkers is thereby the field of cytokine profiling [116] [117] [118] . For monitoring inflammatory processes, a set of these biomarkers reveals relevant information. Regarding the number of assays required to access all cytokine markers in parallel, a massive simplification of assay protocol and sample handling is available by simultaneous multiplex-analysis of different targets in the same sample. While conventional ELISA only analyzes a single target in one assay, the inclusion of alternative detection technologies in the microplate format such as spatial-resolved ECL or bead based technologies increases the number of analytes significantly. In routine analytics, 10 or more cytokines were simultaneously quantified with detection limits typically in the lower pg/ml range [118, 119] .
For a further miniaturization of the assay, DNA signal amplification was combined with the protein-microarray format. Early on in 1995, the obvious combination of multiplex PCR with IPCR was realized in a model assay of three proteins by the workgroup of Ebersole [15, 16] (Fig. 12B) . However, following this initial proof-of-concept, further applications of the multiplex IPCR protocol were extremely scarce [10, 120] . Besides the combined problems of selecting highly specific antibodies and the design of different DNAmarkers and detection systems, conventional PCR is severely limited as a signal enhancement tool for chip-based applications. As amplified DNA is released from the surface, the Fig. (12) . Different technologies for multiplex and polyplex sample analysis: A: In Immuno-Rolling Circle Amplification ("Immuno-RCA"), target-specific detection antibodies are labelled with a short oligonucleotide marker. By addition of a cyclic single-strand DNA reagent containing a complementary sequence and amplification enzyme, the oligonucleotide is elongated with repeated DNA fragments. These are subsequently detected by complementary oligonucleotide probes containing a fluorescence label. As the elongated DNA is still connected to the immobilized antigen, measured signal can be associated to the spot of antigen binding, making this detection technology well suited for microarray applications with different targets. Due to the linear signal amplification, however, the gain in sensitivity is limited. B: In multiplex Immuno-PCR (IPCR), different target antigens are detected by specific antibody-enzyme conjugates containing different marker-DNA sequences. During simultaneous PCR amplification, the DNA is released and the ratio of different product DNAs informs about the amounts of antigens present in the sample. While exponential signal amplification allows for a massive gain in sensitivity, selection of antibody pairs and especially sequence design of marker DNA, primers and detection probes for the amplicon requires great care to avoid unspecific cross-reactivity and/or competitive effects. C: In polyplex analysis, the original sample material is divided in several sub-aliquots, allowing for the detection of different targets in individual assays.
spatial information necessary to discriminate between a large number of immobilized proteins is lost. Using DNA sequence information in combination with specific fluorescent hybridization probes, only a separation of up to 4-5 different DNA-marker molecules is possible in common real-time instruments [121] . Furthermore, the risk of unspecific interaction and competition is increasing dramatically with a higher amount of simultaneously amplified DNA, thus making design of assay conditions, marker sequence, and fluorescent probe quite troublesome. At this point, general challenges of multiplex PCR are taking over [2, 122] . While optimized multiplex PCR is reported for the efficient simultaneous detection of several target molecules [2, 121, 122] , it is at this time not feasible to combine this technology with IPCR in a robust and convenient way as required for routine analysis.
Nevertheless, the properties of DNA allow for an alternative approach to sensitive, minaturized, multiplex protein analysis. In Immuno-RCA (Fig. 12A) , a short oligonucleotide covalently bound to a detection antibody is elongated by a cyclic single strand DNA molecule in rolling circle amplification ("RCA") [123] . In this technique, the elongated DNA remains attached to the detection antibody and thereby the antigen. Following detection with labelled hybridization probes, Schweitzer et al. reported the quantification of 0.1 pg/ml PSA (0.3 amol) [124] as a single analyte model system. In contrast, conventional ELISA carried out under identical conditions revealed a detection limit of 100 pg/ml PSA while other IPCR applications were reported for 60 fg/ml using an ELISA analogous set-up in human serum [53] down to 17 fg/ml in a particle based assay format [36] .
The drawback of an increased number of different samples is thereby once again sensitivity: With an optimized Immuno-RCA protocol, Mullenix and coworkers reported a highly robust 11-plex cytokine assay, detected simultaneously in microarray chip format with a sensitivity of 1pg/ml and below in serum and less than 0.1% cross-reactivity [73] . The number of simultaneously detectable antigens was expanded by Schweitzer et al. with a 51-feature cytokine RCA microarray for measurement of cell secretions [125] and an impressive set of 150 cytokines detected with the RCA method was reported by Shao et al. [126] . In this assay, however, only half of the cytokines were still detectable in the pg/ml range. As signal detection by hybridization probes lacks an exponential amplification, this sensitivity is more equivalent to conventional ELISA -although here with all the handling advantages of miniaturized multiplex analysis.
While scanning of complete cytokine profiles reveals the most significant markers for a given question, broad multiplex analysis is supplemented by individual high sensitive detection of selected biomarkers. Especially for low-level samples and/or challenging sample material, the inclusion of IPCR technology expands data collection. An increase of ELISA detection limits in the scale of several orders of magnitude for single cytokine detection was reported by the Niemeyer group using direct antibody-DNA conjugates for the detection of IL6 [82] or Furuya et al. using a carefully adapted sequential IPCR for the detection of IL 18 [127] . An ultra-sensitive IPCR detection of the single cytokine TNF in the sub-pg/ml range was also reported by several research teams [34, 69, 70] , further underlining the potential of Immuno-PCR applications to support other immunoassays with added sensitivity e.g. by focussing on challenging matrices..
A compromise between single target detection and multiplex analysis is accessible by polyplex assay formats, additionally avoiding potential antibody cross-reactivity (Fig.  12C , see also above, 1.1).
The interaction of different biomarkers is typical for all kinds of regulatory processes. In a study of protein biomarkers influencing muscle growth, a set of two marker proteins was identified for a typical characterization pattern of muscle atrophy, normal individuals and enhanced muscle growth in bodybuilders. The assay thereby allows for both, a deeper understanding in process of muscle development for monitoring and therapy of paraplegic or short/long term paralyzed patients and a control of doping effects in sports. As already the ratio of two proteins was found sufficient for pattern identification, no extensive multiplex assay set-up for multiple markers was required. In addition, a high robustness against different matrices and small sample volumes was desirable for routine analysis instead. Therefore, a highly sensitive two-parameter multiplex and polyplex IPCR was realized, revealing the potential for parallel detection of both markers in samples sizes of 10 microliters or less with a detection limit below 1 pg/ml for follistatin and 0.1 pg/ml for myostatin-propeptide, respectively. The assay which was applied in a WADA-supported long term training study by Diel et al. increased comparable ELISA sensitivity for these antigens a 1000-fold and allowed for muscle growth profiling in different matrices and proband groups [38] .
Another recent focus for research and development is the study of neurodegenerative disorders to improve understanding of the protein processing in brain, CSF and blood and thereby support novel developments in diagnostics and treatment.
Here, Barletta et al. who also advanced virus detection by IPCR [31, 59, 60] reported an improved IPCR assay of lowest levels (< 1000 infectious units) of pathologic prion protein PrP(Sc) in diluted and proteinase K (PK) treated hamster brain, indicating a pathway to detect scrapie and related diseases in the pre-clinical phase of infection [81] . This was confirmed by the use of antibody-RNA conjugates and subsequent T7 RNA polymerase amplification ("FACTT") which revealed prion aggregates in the brain of mice as early as 7 days after an intraperitoneal inoculation of PrP(Sc) and 100% sensitivity and specificity in detecting diseaseassociated prion aggregates in blood of infected mice at late but still asymptomatic stages of disease [128] .
Gofflot et al. also successfully demonstrated the sensitivity of a PrP specific immuno-quantitative PCR with CJD infected humans [129] while Guo and coworkers used PrP as an example for phage display mediated IPCR [41] . Avoiding the PK treatment, also a highly sensitive approach using PrPc(Sc) specific antibodies was already described with more than 1000-fold increased sensitivity in a variety of body fluids [130] , demonstrating once again that a key factor for successful immunoanalytics is indeed the performance of the involved antibodies.
While Scrapie, CJD and related diseases are mostly identified by the prion protein and variations thereof, the mechanism behind Alzheimer's disease (AD) is of a more complex nature. Here, a number of protein families are interconnected and research in this field requires the monitoring of e.g. different amyloid and TAU proteins alike. In using the IPCRrelated bio-barcode technology, the workgroup of Mirkin demonstrated that DNA-enhanced immunoanalytics provides a pathway towards the detection of pathogenic AD markers [131] . As ultra-sensitive analytics proposes major advantages for low level marker detection [132] , the routine IPCR protocol was also adapted to several different AD marker proteins (Fig. 13) , including A 40, 42, oligomeric A and different TAU proteins [110, 133, 134] . At the example of phosphorylated TAU, a research project of Iqbal et al. evaluated the potential of IPCR analytics to enhance conventional ELISA. Abnormally hyperphosphorylated TAU is believed to be a useful marker for neurofibrillary degeneration. TAU is phosphorylated at several different sites and at different levels, thereby increasing the number of analytical targets. In contrast, the amount of CSF available from animal samples is exceedingly small. Therefore an ultra-sensitive IPCR assay was developed which required only 2.5 l of sample material for the detection of <50 fg Ser 199 or Thr 205 phosporylated TAU in CSF. Conventional ELISA formats like the most widely used INNOTEST assay need typically 75 l CSF/assay and IPCR sensitivity was found 100-fold increased compared to an ELISA carried out under identical conditions [135] . The IPCR assay revealed a dynamic range over 3 orders of magnitude and an intra-assay CV below 5%, enabling a quantitative detection of the TAU antigens.
Similar research is at this time carried out for other Alzheimer marker proteins, increasing the range of ultrasensitive targets [103] . After identification of the most significant marker proteins, this set of different targets can once again be compiled to a distinctive poly-or multiplex AD panel, thereby providing a new tool for early diagnosis and monitoring of the disease in different matrices.
In summary, biomarker detection for various target panels and individual target proteins benefits from the use of antibody-DNA detection conjugates at various levels. Increased sensitivity and the ability to realize robust multi-and polyplex detection systems in different biological matrices enables the researcher to access new pathways for the development and monitoring of novel compounds, paralleled by an enhanced and robust observation of biological feedback to disease and treatment.
SUMMARY AND DISCUSSION OF IPCR AS A BIOANALYTICAL TOOL IN ROUTINE ANALYSIS
The potential of ultra-sensitive analytics for applications in routine biomolecule analytics is enormous. With enhanced sensitivity, a number of assays strategies became available which could significantly change what is possible in immunoanalytics today. But, as known for all advances in science, there is no easy solution for each and every problem. A number of different technologies offer tailored solutions for different challenges but no single technology combines all advantages. Of course, there are also massive drawbacks when reality meets up with idealized assay conditions from model studies. For a full evaluation of the usefulness of enhanced sensitivity, the following topics are worth to contemplate:
(I) The Need for Maximum Sensitivity
For many analytical problems, conventional ELISA technologies are already adequate, especially when carefully optimization is coupled with more sensitive detection technologies like fluorescence or chemiluminescence. However, even when the actual detection limit is in the range of a typical ELISA, there may be other reasons to evaluate IPCR and related technologies such as limited amount of available sample material, the need for a broad detection range and/or high robustness against biological matrices.
(II) Comparison between DNA/RNA and Protein Analytics
With the potential for single molecule detection without a direct label, PCR nowadays surpasses all other routine detec- [82] revealed a high assay precision in combination with a dynamic range over several orders of magnitude. Detection limit of comparable ELISA were found at >10 pg/ml for Aß and > 800 pg/ml for TAU, respectively, thereby underlining the gain in sensitivity accessible with IPCR [110, 133, 134] . tion technologies in the analytical laboratory. If an analytical challenge can be traced back to nucleic acids, the degree of optimization, automatization and efficient detection which is available by modern PCR instruments, reagents and protocols certainly advises the use of DNA/RNA analytics. There are, however, analytical questions which are not related to DNA in any form. Especially the detection of pharmaceutically active components in the organism is typically inaccessible by PCR [37, 79] . Furthermore, the ELISA-analogous sequence of incubation and washing steps in IPCR in combination with sample dilution provides a simple and elegant way to circumvent laborious sample-purification steps. PCR inhibitors which may interfere with classical nucleic acid amplification are removed in IPCR by the immunological binding step. DNA/RNA detection alone is also no safe indication of the presence/absence of the expressed protein. Especially in regard to protein functionality or toxicity, an actual detection of the protein in a given sample will add important information [30, 37] . Therefore, ultra-sensitive DNA and protein analysis are not mutually exclusive but ideally supporting each other.
(III) Considerations Regarding the Quality of Reagents, Especially the Specificity of the Antibodies and the Stability of the Antigen
As with all classical immunoassays, high quality reagents are required for IPCR. It makes only very limited sense to evaluate ultra-sensitive analytics as long as no good antibodies are available and/or the target protein is not stable under assay conditions. In this case, it is recommendable to optimize the immunological part of the assay before switching to improved detection systems. Nevertheless, it is worth to remember that the requirements of ultra-sensitive assays are in some fields different from ELISA, especially regarding the amount of actually binding antibody. For IPCR a small number of highly specifc immobilized antibodies is sufficient. Thus, it is helpful to determine the performance of promising antibodies with both, IPCR and ELISA to evaluate the best antibody / antibody pair for a given analytical challenge [79] . Additionally, sample handling has a strong influence on assay performance, especially at lowest target concentrations. It is therefore necessary to test early on the stability of the sample for parameters like diluent, freezing and storage conditions. If sample material e.g from a clinical study is affected by freezing, a simple way to counterbalance storage effects is a similar treatment of both, samples and calibration curve. The high sensitivity of IPCR compensates the loss in sensitivity induced by stressful sample handling and allows for quantitative sample analysis by appropriate calibration curves [78, 79] .
(IV) The Availability of Compatible Reagents and Instruments for Performance of IPCR Assays
A particular advantage of combining the wide-spread ELISA and PCR protocols is the broad distribution of equipment for both technologies. Typically, IPCR requires no special equipment unique for this method. That is, as long as good equipment for immunoanalytics and DNA quantification is provided: A real-time cycler as utilized for standard quantitative PCR is the favourable instrument for DNA detection and the ELISA microplate format is mostly used to facilitate assay handling in the immunoassay laboratory. A microplate washer will extremely simplify assay performance; it also reduces hands-on time and supports reproducibility. Laboratory work should be carried out with care; even as IPCR is highly robust against matrix effects, crosscontamination had to be avoided by appropriate use of the equipment and standardized handling/washing procedures. While different protocols for in-situ antibody-DNA conjugation are reported, there are also nowadays several suppliers and service providers for IPCR and related technologies, including antibody-DNA crosslinking, assay kits, Imperacer, Immuno-RCA and proximity ligation. Similar to ELISA technologies, this liberates the analytical scientist from preparation of required reagents and allows one to focus on the analytical application itself instead of method development.
(V) Robustness of the Assay Format and Compatibility with Routine Analysis
The decisive criteria of assay usefulness is its ability to deliver valid quantitative data in day-to-day applications. Hence, assay specificity and precision are crucial for robust assay performance. By combination of immunoassay technology with enhanced signal amplification, it could be expected that method error is also enhanced and false negative results became a problem due to background noise. In contrast, the combination of quantitative IPCR and real-time detection revealed a very low standard deviation due to the optimized signal generation and data read-out. While in IPCR a negative control could never be absolutely zero due to incubation with DNA-marker previous to amplification, the exponential signal amplification increases the difference between unspecific and specifically bound marker and thereby enables a good separation of positive signals from the negative control. (Fig. 7D.) The key to signal maximization and background minimization is thereby the robustness of optimized assay protocol and a high coupling efficiency between analytical target and DNA-marker. Blocking reagents and sample dilution buffers reduce unspecific background -but it is equally important to raise specific signals. As multiple pipetting, transfer and incubation steps are prone to an add up of individual errors and additionally induce a loss of coupling efficiency [58] , the use of antibody-DNA conjugates in simplified protocols significantly enhances assay performance [54, 82] . A reduced number of handling steps is also an imperative for efficient assay automatization. IPCR protocols in general are compatible with automated washing steps [82, 86] and all three platforms of protein microarrays, bead-based assays, or standardized microplates can be readily supported by appropriate handling automates. The performance of ultra-sensitive assays requires care in definition of standard operating procedures for smallest sample volumes and minute amount of antigens as well as homogenous samples and reagents -but not more so as comparable technologies like PCR. And in contrast to PCR, where the assay has to be adapted to target DNA sequence by complex primer and probe design for each new template, IPCR allows for the design of a robust and interference-free DNAmarker which can be utilized in an idealized amplification, thereby further increasing performance of the signal amplification step. The groundwork for standardized IPCR assay design was carried out over more than 10 years and repeated applications of the technology confirmed its stability for all kinds of immunoassays, including different routine studies [75, 76, 78] . With an effort similar to conventional immunoanalytics, IPCR can be adapted to new analytical targets by synthesis of antibody-DNA conjugates or selection of an appropriate indirect detection reagent, optimization of assay parameters (reagent concentration, sample dilution, etc.), and finally assay validation. These steps are required as for all kinds of routine quantitative analysis -without them, qualitative assays, research evaluations or simple feasibility studies are possible but to fully explore the properties of an analytical technology, a systematic customization is mandatory.
The five focus topics summarized above work as a filter, defining the application fields where ultra-sensitive IPCR is truly meaningful. In some cases, the introduction of a new antibody may solve most problems of a given ELISA and the additional enhancement of assay efficiency by DNA-markers is simply not necessary. But there is always a core of analytical challenges where conventional approaches have failed, where time and/or effort forbid an indefinite optimizing of ELISA, or where novel analytical questions require innovative assay formats. And it is in these applications where IPCR and related technologies can truly prove its worth. They offer new approaches to circumvent problems when a development phase urges for information about performance of a new compound and conventional analytics sets limits to the collection of relevant data. Here, added sensitivity offers a shortcut to quantify low-level signals, work with smallest sample sizes and measure in the biological matrix of choice. Multi-and polyplex detection technologies simplify the detection of multiple parameter panels and the possibilities of enhanced bimolecular interaction analysis increases monitoring of target functionality. Since its introduction in 1992, IPCR has matured over the course of 15 years from a fascinating research concept to a stable and robust technology for routine applications. Thus, the merging of DNA and protein analytics by combination of today's most fundamental immunoanalytic and nucleic acid amplification technologies provides tailored tools for novel developments in the future.
